Previous GeneCards Identifiers for P2RX4 Gene

Summaries for P2RX4 Gene

Entrez Gene Summary for P2RX4 Gene

The product of this gene belongs to the family of purinoceptors for ATP. This receptor functions as a ligand-gated ion channel with high calcium permeability. The main pharmacological distinction between the members of the purinoceptor family is the relative sensitivity to the antagonists suramin and PPADS. The product of this gene has the lowest sensitivity for these antagonists. Multiple alternatively spliced transcript variants, some protein-coding and some not protein-coding, have been found for this gene. [provided by RefSeq, Feb 2012]

GeneCards Summary for P2RX4 Gene

P2RX4 (Purinergic Receptor P2X, Ligand Gated Ion Channel, 4) is a Protein Coding gene.
Diseases associated with P2RX4 include chronic pain.
Among its related pathways are CREB Pathway and Calcium signaling pathway.
GO annotations related to this gene include protein homodimerization activity and copper ion binding.
An important paralog of this gene is P2RX1.

UniProtKB/Swiss-Prot for P2RX4 Gene

Receptor for ATP that acts as a ligand-gated ion channel. This receptor is insensitive to the antagonists PPADS and suramin.

Tocris Summary for P2RX4 Gene

P2X receptors are members of the ligand-gated ion channel family that open in response to extracellular ATP. Each receptor is made up of a trimer of subunits (P2X1-7) all of which share the common structure of two transmembrane domains, a large extracellular loop and intracellular C- and N-termini. Receptors can be formed from triplets of identical subunits (homomeric) and can also exist as heteromers. With the exception of P2X6, all subunits can form homomeric receptors. P2X receptors have a wide distribution throughout the body, including the central, peripheral and autonomic nervous systems, smooth muscle, heart and leukocytes. They are involved in a range of physiological processes such as modulation of synaptic transmission, vascular tone, cardiac rhythm and contractility and nociception.